Home Blog Page 2027

Confluence Legacies of Hetao Culture

BEIJING, Sept. 29, 2025 /PRNewswire/ — A news report from China.org.cn on the Hetao Culture in Northern China:


Confluence Legacies of Hetao Culture

The surging Yellow River has sculpted the fertile Hetao Plain across the northern frontier, where Bayannur gleams like a pearl upon its banks—eagerly awaiting the lens to capture the luminous essence of its distinctive Hetao Culture.

In the primordial dawn, the silhouettes of the “Hetao People” emerge—the land’s earliest pioneers. Amidst ancient chaos, their tenacity and adaptability etched humanity’s early traces along the Yellow River. These ancient vestiges pierce the horizon like the first light through clouds: faint yet brimming with boundless promise. They laid the cornerstone for Hetao’s cultural flourishing, becoming the wellspring from which diverse traditions took root.

Modern Hetao today resonates with the harmony of contemporary life and ancestral heritage. Ancient cultural sites, meticulously preserved and revitalized, now stand as timeless landmarks; cutting-edge agricultural technology amplifies the bounty of this “Northern Granary,” its produce efficiently reaching global markets through seamless logistics; ethnic traditions, reinvigorated by cultural industries, merge age-old craftsmanship with modern design to forge innovative cultural creations. Today’s Hetao strides steadily forward—anchored in profound history yet pulsing with vibrant vitality—embracing the currents of the times.

The Cultural Sit-Down with Wang Xiaohui
http://cul.china.com.cn/node_1008104.htm
Confluence Legacies of Hetao Culture
https://x.com/chinaorgcn/status/1972128327449341989 

Big Tree Cloud Holdings Limited Announces Pricing of $5.0 Million Registered Direct Offering

SHENZHEN, China, Sept. 29, 2025 /PRNewswire/ — Big Tree Cloud Holdings Limited  (“Big Tree Cloud” or the “Company”) (NASDAQ: DSY) (NASDAQ: DSYWW), a capital platform enterprise focused on strategic investment and industry integration in the personal care sector, today announced that it had entered into a definitive agreement in a registered direct offering with an institutional investor for the purchase and sale of 8,064,516 ordinary shares, $0.0001 par value per share (“Ordinary Shares”), at a price of $0.62 per Ordinary Share.

Aggregate gross proceeds to the Company are expected to be approximately $5.0 million, before deducting placement agent fees and offering expenses. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.

The offering is expected to close on or about September 30, 2025, subject to the satisfaction of customary closing conditions.

Aegis Capital Corp. is acting as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-289941) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on September 9, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Big Tree Cloud

Founded in 2020, Big Tree Cloud is positioned as an international capital platform focused on industrial integration and strategic investment in China’s personal care industry. The Company emphasizes scientific research, innovation, and technological advancement, as well as supply chain synergy and efficiency improvement, and is firmly committed to promoting globalization with a mission to empower Chinese personal care brands for global competitiveness and fuel the industry’s high-quality evolution.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or Big Tree Cloud’s future financial or operating performance. In some cases, you can identify forward looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Big Tree Cloud’s expectations, strategy, priorities, plans or intentions. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections and other forward-looking statements will not be achieved. You should understand that a number of factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including the risks discussed in our reports filed or furnished to the Securities and Exchange Commission. Big Tree Cloud cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Big Tree Cloud does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contact
Ting Yan
Phone: +86 15986815865
Email: yanting@bigtreeclouds.com 

TriNetX Named Among the Top 25 Healthcare Software Companies of 2025

Recognition by The Healthcare Technology Report underscores TriNetX’s innovation in real-world data, artificial intelligence, and clinical research transformation.

CAMBRIDGE, Mass., Sept. 29, 2025 /PRNewswire/ — TriNetX, the company behind the world’s broadest federated network of real-world data (RWD) and evidence, has been named one of the Top 25 Healthcare Software Companies of 2025 by The Healthcare Technology Report. This prestigious recognition celebrates TriNetX’s rapid growth, pioneering software solutions, and transformative contributions to life sciences and healthcare.

Top 25 Healthcare Software Companies 2025
Top 25 Healthcare Software Companies 2025

“This recognition reflects the vision we’ve pursued relentlessly: powering innovation across the healthcare ecosystem through data, intelligence, and technology,” said Steve Kundrot, Chief Operating Officer, TriNetX. “By bringing together a global, privacy-compliant network of real-world data with cutting-edge AI and analytics, we’re not only solving today’s clinical research challenges, but we’re also building the foundation for the next generation of precision, representativeness, and speed in drug development.”

TriNetX LIVE™, the company’s flagship platform, integrates de-identified patient data from over 300 million patients across 200+ healthcare organizations and 8,800+ sites around the world. This globally federated, privacy-compliant network fuels clinical trials with deeply enriched datasets including electronic health records (EHRs), genomics, and claims, enabling researchers to build precise patient cohorts and conduct real-time, advanced analyses.

In 2025, TriNetX continues to push boundaries by introducing next-generation features that simplify workflows, improve collaboration, and make data more intuitive to use. The platform’s forthcoming integration of large language models (LLMs) promises to transform how researchers query EHRs, making access to clinical insights as simple as asking a question.

The real-world impact of TriNetX’s technology is evident:

  • AI-driven models show promise in improving patient recruitment and enabling earlier detection in diseases like Crohn’s, pancreatic cancer, and lupus.
  • Protocol optimization tools have helped reduce costly trial amendments by up to 50%.
  • Digital waiting rooms and site intelligence are reshaping how and where clinical trials recruit patients improving representativeness, efficiency, and results.
  • TriNetX’s network has supported over 2,000 peer-reviewed publications and is actively shaping clinical practice, regulatory decisions, and global health policy.

Additional information about The Healthcare Technology Report’s Top 25 Healthcare Software Companies of 2025, including the full list of awardees, can be found on their website.

About TriNetX, LLC
TriNetX operates the world’s broadest federated network of real-world data in partnership with healthcare providers and applies intelligence that accelerates innovation across the healthcare ecosystem. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com

 

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

  • HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply

HONG KONG, Sept. 29, 2025 /PRNewswire/ — Health Hope Pharma Limited (“HHP”) today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. (“Gilead”) for encequidar, a first-in-class P-glycoprotein (“P-gp”) inhibitor in the field of virology.

HHP is currently exploring the potential of using encequidar to develop oral drug formulations across multiple fields. The most advanced program of HHP is oral paclitaxel combined with encequidar in the field of oncology, targeting to replace intravenous paclitaxel in chemotherapy for metastatic breast cancer. HHP targets to recruit the first patients for its global phase III clinical study for sites in the U.S. and Hong Kong SAR, respectively, by the fourth quarter of 2025.

Under the agreement, HHP and Hanmi Pharm (“Hanmi”) will grant Gilead exclusive global rights to encequidar within the field of virology. In addition, HHP and Hanmi will provide drug supply, share technical know-how, and participate as key project partners. HHP and Hanmi will each receive an upfront payment and are eligible to receive development, regulatory and sales milestones in addition to low single-digit royalties on net sales.

Prof. Dennis Lam, founder of HHP said: “We are pleased to announce the licensing agreement with Gilead and Hanmi. This demonstrates the potential of encequidar as a first-in-class P-gp inhibitor to create more oral formulations in multiple fields. This agreement is also a milestone of successful innovation for both the Hong Kong biotech industry and HHP as a biotech company headquartered in Hong Kong. We will build on this momentum to accelerate HHP’s development of oral paclitaxel combined with encequidar and explore other applications of encequidar in oral formulations.”

Jae-Hyun Park, CEO of Hanmi said: “This agreement validates Hanmi’s formulation technology and R&D capabilities, while also opening the door to new growth opportunities through collaboration with a leading global partner. We will continue to expand strategic partnerships that can accelerate innovation and patient access worldwide.”

HHP is preparing for the commencement of global clinical trials of oral paclitaxel combined with encequidar in the U.S., Hong Kong SAR, and New Zealand, with plans to launch the product in Europe, Asia, and the U.S.

About Health Hope Pharma

Health Hope Pharma is a clinical-stage oncology biopharma headquartered in HK SAR and with operations in the U.S. and the U.K., dedicated to developing novel oral anti-cancer drugs towards a safer and more convenient alternative to conventional intravenous therapy. Our flagship drug, oral paclitaxel combined with encequidar, aims to replace the widely used intravenous paclitaxel with its oral equivalent and improve the quality of life of patients.

About Hanmi Pharm

Hanmi Pharm is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes open innovation and has established numerous global partnerships to advance its research and development efforts.

Media Relations & Investor Relations
contact@healthhopepharma.com

The Laughing Cow Wins Big: Bel Group Strengthens Regional Presence with Multiple Awards Across Southeast Asia

JAKARTA, Indonesia, Sept. 29, 2025 /PRNewswire/ — Bel Group, a global leader in branded cheese and healthy snacking, has deepened its bond with consumers across Southeast Asia, with The Laughing Cow earning multiple distinguished awards in 2025 that celebrate both trust and innovation. The accolades highlight the brand’s growing influence among families and its excellence in quality and consumer engagement across the region.

The Laughing Cow Wins Big: Bel Group Strengthens Regional Presence with Multiple Awards Across Southeast Asia
The Laughing Cow Wins Big: Bel Group Strengthens Regional Presence with Multiple Awards Across Southeast Asia

The recognitions include Parents’ Choice Awards 2025 (Malaysia)Best Cheese Brand for Families; BabyTalk + MamaPapa Readers’ Choice Awards 2025 (Malaysia)Best Cheese Wedges for Kids; Asia Excellence Awards 2025Best Digital Marketing Campaign for The Laughing Cow South East Asia and Asia Excellence Awards 2025Best Food & Grocery Brand of the Year (Dairy Products) for The Laughing Cow Creamy Cheese Triangles, South East Asia.

With consumer-voted awards in Malaysia and regional industry recognition across Southeast Asia, The Laughing Cow continues to reinforce its role as a trusted household brand, combining its rich legacy with modern relevance. “These awards not only reflect the trust and love families have for The Laughing Cow, but also the dedication of our teams across the region,” said Alamjit Singh Sekhon, General Manager, Bel South East Asia. “Guided by Bel’s global philosophy of providing accessible, nutritious, and enjoyable food ‘for all, for good,’ we are inspired to keep innovating and growing with purpose in Southeast Asia.”

The Laughing Cow has always upheld a commitment to both nutrition and local values. With a century-long legacy of bringing nutritious, enjoyable products to families globally, Bel Group maintains rigorous quality and safety standards. Two portions of The Laughing Cow Creamy Cheese Triangles provide the same amount of calcium as one glass of milk (170 ml) (Source: HealthHub Singapore). The brand in Southeast Asia only uses high-quality dairy ingredients, with no vegetable oil, no added preservatives, and no artificial colours, making it a protein- and calcium-rich snack that is both nutritious and accessible for children and families.

Bel’s iconic portfolio includes The Laughing Cow Creamy Cheese Triangles, Belcube, Cheez Dippers, and other popular Bel brands such as Babybel and Kiri. These products are available at leading supermarkets, hypermarkets, stores, as well as popular e-commerce platforms, along with your neighbourhood mom-and-pop stores in Southeast Asia.

As Bel continues its journey in Southeast Asia, its vision remains clear: to shape the future of healthy snacking while making food joyful, inclusive, and sustainable for all, for good.

About Bel 

The Bel Group stands as one of the global leaders in branded cheese and healthy snacking. With a diverse portfolio, including The Laughing Cow, Kiri, Babybel, Boursin, Nurishh, Pom’Potes, GoGo squeeZ, and other local brands, they achieved €3.6 billion in sales in 2023. Committed to providing healthier and more responsible food for all, the group boasts 10,902 employees across 30 production sites, distributing its products to nearly 120 countries.

The Laughing Cow Cheese has a rich legacy spanning over a century, promoting happiness and laughter among children and families with its nutritious range of cheese products, adding a daily dose of joy.

 

Plasmatreat GmbH: Plasma Technology Supports the Automotive Industry in Terms of Quality and Sustainability

STEINHAGEN, Germany, Sept. 29, 2025 /PRNewswire/ — The industry is facing major challenges, such as new materials, lightweight construction concepts, and growing sustainability requirements, which call for innovative manufacturing processes. Plasma technology plays a key role in meeting these challenges.

Activation of an automotive dashboard before lamination. (Copyright: Plasmatreat GmbH)
Activation of an automotive dashboard before lamination. (Copyright: Plasmatreat GmbH)

Plasmatreat GmbH develops customized applications for this purpose. The Openair-Plasma® process gently and environmentally friendly pretreats surfaces. This allows materials such as plastic, metal, and glass to be precisely cleaned and prepared for further processing. This significantly improves the adhesion of adhesives, paints, coatings and sealants without using environmentally harmful chemicals.

Additionally, these processes are dry, fully automatable, and can be integrated directly into existing production lines. This increases efficiency, reduces waste, and lowers costs. At the same time, durable bonds contribute to higher product quality and longer component life.

What exactly is plasma?

Often referred to as the “fourth state of matter,” plasma joins solid, liquid, and gaseous states. It is a high-energy gas that modifies surfaces specifically. At Plasmatreat, this modification is done in a controlled and precise manner using special nozzles. The treatment takes only seconds and immediately prepares surfaces for further processing.

Practical examples:

Plasma technology has already established itself in numerous areas of automotive production.

  • Headlights: Treating plastic parts ensures permanent adhesion and protects against moisture.
  • Interior: Pretreated surfaces allow for precise, solvent-free processing of dashboards and door modules.
  • Batteries: In electromobility, plasma improves thermal conductivity in bonded cells, resulting in shorter charging times.

Potential for Other Industries

In addition to the automotive industry, other industries benefit from plasma applications, including electronics manufacturing, medical technology, and the packaging industry. Plasma opens up new possibilities wherever reliable adhesion, clean surfaces, and environmentally friendly processes are required.

Technology for Tomorrow’s Mobility

Plasma applications are important for quality, efficiency, and sustainability in vehicle production. They support the use of modern materials and are therefore a building block for the mobility of the future.

Those interested in learning more about plasma applications will have the opportunity to do so at the K trade fair in Düsseldorf in October (Hall 11, Booth I65).

www.plasmatreat.com

 

Openair-Plasma® treatment enables chemical- and primer-free bonding, painting, printing and sealing and is already established in many processes in the automotive industry.(Copyright: Plasmatreat GmbH)
Openair-Plasma® treatment enables chemical- and primer-free bonding, painting, printing and sealing and is already established in many processes in the automotive industry.(Copyright: Plasmatreat GmbH)

 

 

CeraVe and L’Oréal Groupe Win Prestigious IFSCC Applied Research Award for Breakthrough Dandruff Study

New findings reveal critical microbial drivers, ethnic variations, and new pathways for personalized scalp care

NEW YORK, Sept. 29, 2025 /PRNewswire/ — CeraVe and L’Oréal Groupe today announced that their collaborative study on scalp biology has received the Applied Research Award at the 35th International Federation of Societies of Cosmetic Chemists (IFSCC) Congress, recognizing a breakthrough in understanding dandruff and advancing scalp barrier science.

“Receiving the IFSCC Applied Research Award is a testament to our joint commitment to scientific innovation and understanding the intricate biology of skin and scalp barrier health,” said Gene Colón, Global Senior Vice President, Medical Affairs & Communications for CeraVe at L’Oréal. “This game-changing research moves beyond the traditional view of dandruff to highlight the role of ceramide deficiency and scalp barrier dysfunction, the critical bacterial component and the impact of ethnicity. It significantly expands our scientific understanding, rooted in our foundational ceramide science, offering new perspectives and possibilities for future innovations.”

This award-winning research – the first scalp study of its kind – compared dandruff-affected and healthy scalps, assessing clinical symptoms, ceramide profiles, microbiome composition, and inflammatory markers to provide the most comprehensive picture of dandruff pathophysiology to date. Researchers from L’Oréal evaluated over 200 participants from diverse racial and ethnic backgrounds.

“This recognition reflects L’Oréal’s Research & Innovation teams’ leadership in scientific innovation and our mission to pioneer skin, hair, and scalp science continuously,” said Qian Zheng, Ph.D., Senior Vice President of Advanced Research for North America and Global Head for Regenerative Beauty at L’Oréal Groupe. “By integrating microbiome research with barrier biology through an inclusive lens, our teams are pioneering new approaches to scalp care – translating deep biological insights into targeted, effective solutions for consumers around the world.”

Importantly, this new and previously unpublished study builds on earlier microbiome research, which was published in the Journal of Drugs in Dermatology, while significantly expanding its scope. Whereas previous work characterized the scalp microbiome in a global population, the IFSCC-recognized study goes further — providing a deeper analysis by examining differences across ethnic groups and, for the first time, exploring the functional profile of the microbiome. These new dimensions — combined with insights into microbial targets beyond Malassezia (a naturally occurring fungus on the scalp that has long been associated with dandruff) and their connection to inflammation — represent a major advance in understanding dandruff biology. Key discoveries include:

  • Bacterial drivers: Staphylococcus aureus (S. aureus) and Staphylococcus capitis (S. capitis) — two types of bacteria commonly found on the skin — were consistently more abundant in dandruff across all ethnicities.
  • Strong S. aureus link: A significant positive correlation was identified between S. aureus abundance and dandruff presence and severity.
  • Virulence factors: Dandruff scalps showed significantly higher virulence factor (VF) gene levels, particularly in Latin/Hispanic and Asian American groups, with many VFs previously linked to S. aureus pathogenicity.
  • Personalized treatment: This is the first study to characterize dandruff scalp microbiome function across ethnicities, underscoring the need for diverse, personalized treatment approaches.
  • Ethnic variations: Malassezia levels were higher in dandruff across all ethnic groups except Asian Americans, and Malassezia globosa, one of the most prevalent species associated with scalp health, was prevalent on healthy scalps in all populations.

The IFSCC Congress, held annually and recognized as the most international prestigious global events in cosmetic science, brings together leading stakeholders to showcase cutting-edge scientific advancements.

About CeraVe 
Founded in 2005 with a mission to provide therapeutic skincare for all, CeraVe creates products developed with dermatologists to restore and maintain the skin’s natural barrier. All CeraVe formulas are enriched with three skin-identical ceramides (ceramides 1, 3, and 6-II), with select products featuring MVE Technology for controlled, long-lasting hydration. CeraVe is the #1 dermatologist-recommended skincare brand in the US1 and is recommended by over 90,000 dermatologists worldwide2. It is now available in over 100 countries across the globe. For more information, visit the brand on Facebook (@ceraveusa), Instagram (@cerave), TikTok (@cerave), X (@cerave), or visit www.cerave.com.

1IQVIA, ProVoice Survey, rolling 12-month data as of February 2025
2Survey conducted among the dermocosmetic market carried out by APLUSA and other partners between January 2025 and May 2025, involving dermatologists in 29 countries.

About L’Oréal
For 115 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as essential, inclusive, ethical, generous and committed to social and environmental sustainability. With our broad portfolio of 37 international brands and ambitious sustainability commitments in our L’Oréal for the Future program, we offer each and every person around the world the best in terms of quality, efficacy, safety, sincerity and responsibility, while celebrating beauty in its infinite plurality.

With more than 90,000 committed employees, a balanced geographical footprint and sales across all distribution networks (ecommerce, mass market, department stores, pharmacies, perfumeries, hair salons, branded and travel retail), in 2024 the Group generated sales amounting to 43.48 billion euros. With 21 research centers across 13 countries around the world and a dedicated Research and Innovation team of over 4,000 scientists and 8,000 Digital talents, L’Oréal is focused on inventing the future of beauty and becoming a Beauty Tech powerhouse.

In 2025, L’Oréal Groupe has been named the most innovative company in Europe by Fortune magazine, out of 300 companies, in a ranking spanning 21 countries and 16 industries in Europe.

More information on https://www.loreal.com/en/mediaroom

Media Contacts:
CeraVe: Christine Alkhawamchristine.alkhawam@loreal.com
Coyne PR: cerave@coynepr.com

SLiquid to Debut Southeast Asia-Specific Liquid Cooling CDU at DATA CENTRE WORLD ASIA


SINGAPORE – Media OutReach Newswire – 29 September 2025 – From October 8 to 9, SLiquid Global DataCenter (Singapore) PTE. LTD. (hereinafter referred to as “SLiquid”), an innovative practitioner in the liquid cooling industry, will participate in DATA CENTRE WORLD ASIA—the largest data center event in the region. At the exhibition, SLiquid will unveil its first liquid cooling CDU (Coolant Distribution Unit) specifically designed for the Southeast Asian market.

As data centers in Southeast Asia continue to expand rapidly, they are also facing a range of complex challenges. On the cooling front, surging demand for computing power has pushed up chip heat output, and coupled with the region’s tropical heat, traditional air cooling systems are reaching their performance limits. In terms of energy efficiency and sustainable development, countries like Singapore have introduced stringent PUE (Power Usage Effectiveness) regulations. Meanwhile, the high energy consumption of conventional cooling systems is driving up operational costs, putting data centers under dual pressure from policy compliance and cost control.

In addition, further development of data centers is also constrained by challenges including limited data hall space, increased operational complexity, reduced flexibility for scaling, and demands for higher operational stability.

Against this backdrop, liquid cooling is emerging as a breakthrough technology. Compared to traditional air cooling, liquid cooling offers significantly higher thermal efficiency, better energy consumption control, and longer hardware lifespan. Industry insiders reveal that SLiquid’s upcoming CDU product is designed with ultra-high energy efficiency, high-density and flexible scalability, robust reliability, and simplified maintenance — making it well-positioned to address the specific needs of the Southeast Asian market.

Headquartered in Singapore, SLiquid is a liquid cooling company founded on the profound industry experience of its team. The company has established three core pillars of capability: end-to-end service, liquid cooling and thermal management solutions, and comprehensive regional operations and maintenance.

With teams and operations across Singapore, Malaysia, and Qingdao, SLiquid has built an efficient and collaborative system covering R&D, manufacturing, and delivery. This setup enables faster response times and greater cost efficiency, while also offering scalable and replicable liquid cooling solutions to support the green transformation of data centers across the region.

Hashtag: #SLiquid

The issuer is solely responsible for the content of this announcement.